- Home
- QNCX vs SER Comparison
QNCX vs SER Comparison
Compare QNCX & SER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | QNCX | SER |
|---|---|---|
| Founded | 2012 | 2017 |
| Country | United States | United States |
| Employees | N/A | 13 |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.9M | 19.4M |
| IPO Year | 2019 | N/A |
Fundamental Metrics
Financial Performance| Metric | QNCX | SER |
|---|---|---|
| Price | $1.04 | $1.96 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | N/A | ★ $15.00 |
| AVG Volume (30 Days) | ★ 1.4M | 82.2K |
| Earning Date | 04-10-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.88 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $0.38 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.08 | $1.22 |
| 52 Week High | $4.55 | $7.92 |
Technical Indicators
Market Signals| Indicator | QNCX | SER |
|---|---|---|
| Relative Strength Index (RSI) | 46.14 | 56.43 |
| Support Level | $0.79 | $1.76 |
| Resistance Level | $1.45 | $2.30 |
| Average True Range (ATR) | 0.13 | 0.17 |
| MACD | -0.03 | 0.02 |
| Stochastic Oscillator | 44.64 | 87.50 |
Price Performance
Historical ComparisonAbout QNCX Quince Therapeutics Inc.
Quince Therapeutics Inc is a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases. Its proprietary AIDE technology is an inventive drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells. Its Phase 3 asset, eDSP, leverages the AIDE technology to encapsulate DSP into a patient's own red blood cells, and is targeted to treat a rare pediatric neurodegenerative disease, A-T.
About SER Serina Therapeutics Inc.
Serina Therapeutics Inc is a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and pain. Serina's POZ Platform delivery technology is engineered to provide control in drug loading and more precision in the rate of release of attached drugs, enabling the potential of certain challenging small molecules, while addressing the limitations of polyethylene glycol (PEG) and other biocompatible polymers. The Company has one reportable segment relating to the research and development of its POZ platform.